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Abstract
Background: Real-time PCR is increasingly being adopted for RNA quantification and genetic
analysis. At present the most popular real-time PCR assay is based on the hybridisation of a dual-
labelled probe to the PCR product, and the development of a signal by loss of fluorescence
quenching as PCR degrades the probe. Though this so-called 'TaqMan' approach has proved easy
to optimise in practice, the dual-labelled probes are relatively expensive.
Results: We have designed a new assay based on SYBR-Green I binding that is quick, reliable, easily
optimised and compares well with the published assay. Here we demonstrate its general
applicability by measuring copy number in three different genetic contexts; the quantification of a
gene rearrangement (T-cell receptor excision circles (TREC) in peripheral blood mononuclear
cells); the detection and quantification of GLI, MYC-C and MYC-N gene amplification in cell lines and
cancer biopsies; and detection of deletions in the OPA1 gene in dominant optic atrophy.
Conclusion: Our assay has important clinical applications, providing accurate diagnostic results in
less time, from less biopsy material and at less cost than assays currently employed such as FISH
or Southern blotting.
Background
The detection and quantification of gene rearrangement,
amplification, translocation or deletion is a significant
problem, both in research and in a clinical diagnostic set-
ting. Real-time PCR has become a well-established proce-
dure for quantifying levels of gene expression [1–3]. Its
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PCR, the amount of PCR product (amplicon) using fluo-
rescence. Several approaches have been employed to
detect PCR products. The most popular, the 5'-nuclease
assay, is based on the specific hybridisation of a dual-
labelled TaqMan [4] probe to the PCR product. Another
approach is based upon the binding of the fluorescent dye
SYBR-Green I into the PCR product (PE Applied Biosys-
tems, Warrington, UK). Although both assays are poten-
tially rapid and sensitive, their principles of detection and
optimisation are different, as is the resulting price per
assay. Here we report the development and rigorous test-
ing of a real-time PCR assay using the inexpensive SYBR-
Green I technology.
We developed our assay initially for the detection of a
gene rearrangement in the T-cell receptor locus. The
immune system requires a large diversity of immunoglob-
ulins (Ig) and T-cell receptors (TCR) to screen the body for
pathogens. Such diversity is achieved by rearranging pre-
existing segments of the TCR or IG genes randomly [5].
This process involves the excision of intervening segments
of DNA, the ends of which are subsequently ligated to
form T-cell reception excision small circles of episomal
DNA (TRECs – Figure 1). The level of TRECs in peripheral
blood mononuclear cells provides a surrogate measure of
thymic activity and as such, there is a need for a rapid,
cheap and reliable assay to quantify TRECs in clinical sit-
uations where the immune system may be compromised.
Formation of TRECsigure 1
Formation of TRECs. During their passage through the thymus, T-cell precursors rearrange their T-cell receptor (TCR) 
genes. This step requires the excision of segments of DNA, the ends of which are subsequently ligated to form small circles of 
episomal DNA (signal and coding), hereafter referred to as T-cell receptor excision circles (TRECs). The sequences remaining 
after recombination provides the target for a PCR detection of TREC. Each mature T-cell exiting the thymus and released into 
the circulation, therefore contains episomal TRECs. As these cells replicate in the peripheral blood, TRECs are not replicated 
but are distributed among daughter cells and are gradually diluted in the peripheral T-cell pool. Therefore, by measuring the 
proportion of peripheral T-cells containing TRECs, an estimate of recent thymic function can be obtained.
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applicability of our assay by using it to quantify other
genetic events. Firstly we assayed gene amplification in
cancer. The glioma-associated oncogene GLI was identi-
fied in 1987 and found amplified in double minutes in
glioblastoma [6]. It was mapped by in situ hybridisation
to 12q13-14 [7] a chromosomal region demonstrating
amplification in subsets of glioblastomas and sarcomas
[8,9]. We used our assay to quantify GLI amplification in
five tumor-derived cell lines. Similarly the MYC oncogene
is amplified in a number of pathologies, particularly in
neuroblastoma where MYC-N amplification is a diagnos-
tic marker [10]. We quantified MYC-C amplification in
cell lines and MYC-N amplification in a set of tumour
samples where it was associated with a diagnostic and
prognosis of neuroblastoma [10].
Lastly we assayed genomic copy number as a test for gene
deletion in a dominant Mendelian disorder. Autosomal
dominant optic atrophy (ADOA) is the most common
hereditary optic neuropathy, resulting in progressive loss
of visual fields, colour vision defects and in many cases
registered blindness. The most common cause of ADOA is
mutations in the OPA1 gene on chromosome 3q28-q29.
Many different mutations have been described in families
with ADOA, including point mutations, small deletions
and insertions [11] and the deletion of either the entire
gene [12] or of exon 20 alone [13]. We applied our assay
to the detection of a micro-deletion of the OPA1 gene in a
family with ADOA where such a deletion had previously
been identified.
Results and Discussion
The principle of Real-time PCR quantification
A real-time-PCR read-out is given as the number of PCR
cycles ("cycle threshold" Ct) necessary to achieve a given
level of fluorescence. For this study, the Ct was fixed in the
exponential phase of the PCR (Figure 2A, linear part of the
fluorescence curve). During the initial PCR cycles, the flu-
orescence signal emitted by SYBR-Green I bound to PCR
product was usually too weak to register above back-
ground. Indeed, a difference could not be defined until
after about 15 PCR cycles. During the exponential phase
of the PCR the fluorescence doubled at each cycle. After 35
cycles, the intensity of fluorescent signal usually began to
plateau, indicating that the PCR had reached a saturation
status. As a Ct is proportional to the logarithm of initial
amount of target in a sample, the relative concentration of
one target with respect to another is reflected in the differ-
ence in cycle number (∆Ct) necessary to achieve the same
level of fluorescence (Figure 2A).
Optimisation of Real-time PCR conditions
Optimal design of the PCR primers is essential for accu-
rate and specific quantification using real-time PCR. For
the assay described herein, detection is based on the bind-
ing of the SYBR-Green I dye into double stranded PCR
products, which is a sequence independent process. While
this assay is cheaper than the more commonly used 5'
nuclease assay, it loses the additional level of specificity
introduced by the hybridisation of the PCR product to a
specific fluorescent TaqMan probe. The sensitivity of
detection with SYBR-Green I may therefore be compro-
mised by the formation of primer-dimers, lack of specifi-
city of the primers, primer concentration (which can be
limiting) and the formation of secondary structures in the
PCR product. All of these factors could lead to the creation
of unexpected double-stranded DNA product, which
would incorporate SYBR-Green I and register a fluorescent
signal. The 5'-nuclease assay using TaqMan probes would
also be compromised by primer dimers. Although they are
not detected, they do alter the amplification efficiency of
the specific product.
The optimisation of the primer concentration is essential.
Each set of primers work best under different concentra-
tion conditions. Primer design is also very restrictive: the
annealing temperature is restricted to 58–60°C, which
corresponds to the optimal working conditions for the
AmpliTaq Gold DNA polymerase enzyme (Perkin Elmer),
and the length of the PCR product is set between 80 and
150 bp. The use of software dedicated to RT-PCR primer
design, such as Primer Express™ (Perkin Elmer), is highly
recommended. For all experiments described in this
report, each pair of primers was designed following the
manufacturer's instructions to amplify products from the
genes of interest ranging from 81 to 122 bp (Primer
Express™, Perkin Elmer). Primer concentration is usually
determined to be optimal when specific amplification rel-
ative to primer-dimers was maximal in a positive versus
negative control experiment. However, the choice of the
most appropriate conditions for our assay corresponds to
the combination of primer concentration allowing a ratio
of target gene to reference gene of 1 in a DNA sample with
no genetic abnormality. This ratio is calculated using the
∆Ct methods (∆Ct = Ct of the target – Ct of the reference).
A delta Ct of 0 indicates a ratio of 1 between the target and
the reference (2-(∆Ct) = 20 = 1). A number of factors can
influence this assay, and the optimisation consists in com-
pensating these factors to obtain a ratio of 1 in a DNA
sample with no genetic abnormality. The inclusion of
such a normal DNA sample on each experiment also pro-
vides a reference sample for a ∆-∆Ct method of calcula-
tion, however, as the normalisation will relate to a value
close to 0 for the second ∆Ct, both methods essentially
give the same result.Page 3 of 13
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Real-time Optimisation. A). Real-time amplification plot. Three real-time amplification plots are shown for GAPDH as 
target 2, GLI as target 1 and no-template controls (background at the bottom of the graph). DNA from the SJSA1 cell line was 
used for this experiment. The cycle numbers (cycle threshold, Ct) necessary to achieve the given level of fluorescence of 2 
(horizontal line), which lies in the log-linear phase of both PCR reactions, were 27.03 and 32.25 for target 1 and 2 respectively 
(vertical lines). A difference of 32.65-27.03 = 5.62 cycles between the two Ct, means that there was 25.62= 49.2 more of target 
1 relative to target 2. This confirms an amplification of the GLI gene in this cell line. B) and C). Dissociation curves for 
GAPDH (B) and signal TREC (C) PCR reactions. Dissociation curves provide a graphical representation of the PCR 
product after the amplification process. A single peak in positive samples (graph +) suggests a single size product (GAPDH 
amplification from PBMC DNA). An absence of peak in the negative control sample (graph -) indicates the lack of primer 
dimer. Occasionally, primer-dimers were observed in negative control wells, (as shown by the arrow on plot C for signal TREC 
amplification from PBMC DNA). The melting temperature of each PCR product varies and is dependent on its sequence and 
size. A melting temperature of 81°C was observed for the GAPDH product (84 bp), which contained 17 Gs, 29 Cs, 17 As and 
21 Ts. The signal TREC product (122 bp) had a melting temperature of 87°C and contained 19 Gs, 25 Cs, 33 As and 45 Ts. The 
occasional primer-dimers (indicated by the arrow on graph C) have a much lower melting temperature. D) Primer concen-
tration optimization. Three sets of primers were designed to amplify 3 target genes (OPA1, MYC-C and GLI). A primer con-
centration optimization experiment was performed where all PCR conditions were the same apart from the primer 
concentration. The same PBMC DNA sample was used in all tests. Normalization was performed against GAPDH in this DNA 
sample using the delta Ct method. The primer concentration used for GAPDH in this assay was 100 nM. MYC-C (black bars) is 
optimally amplified at the concentrations of 500 nM for both primers with a ratio of 0.99. GLI (grey bars) is similarly detected 
over concentrations ranging from 100 to 500 nM for both primers however, with an optimal ratio of 0.98 at 300 nM. OPA1 
(open bars) is only detected at a primer concentration of 500 nM with a ratio of 0.95. Of note, excess of primer is detrimental 
to all 3 PCR assay as amplifications yielded less product for the 3 different targets at concentrations of 1000 nM for each 
primer.
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a PCR negative control (Figure 2B and 2C), however, in an
experimental negative including a template but no target,
dimers were not observed. Furthermore, the inclusion of
a heat dissociation experiment at the end of the PCR sug-
gests that a single product is present (even if an electro-
phoresis is used once at the end of the first optimisation
plate to confirm it). The degree of an eventual primer-
dimer contribution (Figure 2C) to the overall fluorescent
signal of the PCR negative control can also be detected in
such a dissociation experiment. As an example, 3 sets of
primers were used to amplify 3 targets (OPA1, GLI and
MYC-C) in an optimisation assay where the only variable
was the concentration of primers in the reaction (Figure
2D). For these examples, the concentration of primer for
GAPDH was 100 nM for GLI and MYC-C and 50 nM for
OPA1. However, for other target genes it was necessary to
either increase or decrease the primer concentration for
GAPDH (see Table 1). For this demonstration, we used
normal PBMC derived DNA template and normalised the
expression of these 3 target genes to GAPDH. The optimi-
sation experiment consists in finding the conditions nec-
essary to obtain a ratio of for target gene to reference. The
first set of primers (black bars, MYC-C) showed a bell
shaped optimisation pattern where the intermediate con-
centrations were optimum and giving ratio of target to ref-
erence close to 1. The second set of primers (grey bars,
OPA1) showed a plateau type of curve where most of the
higher concentrations were of similar efficiency. The last
primer set (open bars, GLI) showed poor amplification at
both extremes of the concentration range, and a single,
efficient concentration of primer. In these optimisation
experiments, primer dimers were not observed. Higher
primer concentration had a limiting effect on the PCR
reaction and would be detrimental to the accuracy of the
quantification.
For an accurate quantification it is also necessary to verify
that PCR efficiency is independent of the initial amount of
target DNA. Each pair of primers was therefore tested
across several logs dilution series of a positive control
DNA sample. Figure 3A shows such an experiment for
TREC quantification (coding and signal). It was necessary
to use cloned template for this purpose, as a TREC rear-
rangement sequence is not available in genomic DNA.
The two plots obtained for the signal and coding TREC
(and the internal reference gene, GAPDH), were linear,
demonstrating equal efficiency of the individual PCR
assays over a large range of initial template concentra-
tions. The titration plots were also super-imposed, dem-
onstrating that the three PCR assays were equally efficient
despite the differences in PCR product sizes and base pair
constitution. Similar experiments were performed for all
the other genes, using genomic DNA however (data not
shown, and Table 1).
DNA quantification
One of our major aims was to determine the limit of sen-
sitivity of our assay in allowing accurate quantification of
gene amplification, deletion or rearrangement from DNA
extracted from relatively few cells. For this purpose we
estimated the number of cells present in a given sample by
real-time PCR quantification of the copy number of the
housekeeping gene GAPDH, each cell having two allelic
copies of this gene. In principle, any gene would be suita-
ble, however, as we were expecting to look at deletions,
amplifications and rearrangements, we chose a gene that
was unlikely to be involved in any of these processes. We
have assayed the linearity of the relationship between
real-time Ct for GAPDH reading with cloned GAPDH tar-
get. The use of cloned template also provided a read-out
that reflected the number of molecules present in the
reaction, which could then be used for an absolute quan-
tification (see Figure 4A). Therefore, Figure 3A also shows
Table 1: Real-time nucleotide primer sequences
PRIMER 
CONCENTRATION &
PCR EFFICIENCY *
GENE FORWARD PRIMER REVERSE PRIMER ACCESSION 
NUMBER
PRODUCT 
LENGTH
REFERNCE 
GENE
TARGET 
GENE
REFERNCE 
GENE
TARGET 
GENE
hGAPDH AAC AGC GAC ACC CAT CCT C; CAT ACC AGG AAA TGA GCT TGA CAA NM_002046 81
CODING CAC CTC TGG GCT ACG TGC TAG GAA CAC ATG CTG AGG TTT AAA GAG AAT NG_001332 98 50/50 300/300 -2.87 -2.84
SIGNAL CAG AGG GGT GCC TCT GTC A GGA CCC CTC ACA AAG TGT CG NG_001332 142 100/100 100/100 -2.87 -2.93
C-MYC TTC TAA GAG AAA TGT CCT GAG CAA TC TCA AGA CTC AGC CAA GGT TGT G X00364 88 100/100 500/500 -3.18 -3.22
GLI CCC AAT CAC AAG TCA GGT TCC T CCT ATG TGA AGC CCT ATT TGC C NM_005269 93 100/100 300/300 -3.18 -3.19
N-MYC CTT TCA AAT CGG TCC CCT GTC AGA GGT TCC AGG GTC GTC TT Y00664 82 50/50 300/300 -3.29 -3.30
OPA1 TGT GAT TGA AAA CAT CTA CCT TCC A TTT AAG CTT GAT ATC CAC TGT GGT GT NM_015560 82 50/50 500/500 -3.34 -3.38
MGAPDH GTC TCC TGC GAC TTC AGC TCA TTG TCA TAC CAG GAA ATG AGC NM_008084 107
HOP TGG AGT ACA ACT TCA ACA AGG TCA A GGA CTC ACC TGC GTC TGC TC. AF492703 103 50/50 300/300 -3.2 -3.18
FLAG/
HOP
ATG GAC TAC AAG GAC GAT GAC CGA TGT TGA CCT TGT TGA AGT TGT ACT CC AF492703 107 50/50 100/100 -3.2 -3.21
& Concentrations used in individual assay for F/R primers (nM). * PCR efficiency defined as the slope of the Log-linear phase of a dilution set as described in Figure 3APage 5 of 13
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number of cloned GAPDH molecules, allowing us to cor-
relate the GAPDH-Ct of a sample with a number of
GAPDH molecules. This number, when divided by 2,
would thereby correspond to the number of cells from
which the DNA was initially extracted. We assayed the
relationship between the amount of DNA in cell extracts
and GAPDH readings. The relationship between GAPDH-
Cts and the spectrophotometer-measured concentrations
of forty genomic DNA samples extracted from PBMCs
under the same conditions but at different times and by
different research workers is linear as demonstrated in Fig-
ure 3B. The relationship between the initial number of
cells in a sample and the DNA concentration of the same
sample was also linear (data not shown), indicating a sim-
ilar efficiency of the DNA extraction method without
DNA quantification using the SYBR-Green I assayFigure 3
DNA quantification using the SYBR-Green I assay. A). The sensitivity of the GAPDH, signal and coding TREC 
PCR assays are similar. Titration curves were obtained by taking cloned GAPDH, signal and coding TREC templates of 
known concentration and using these to create a seven log dilution series for each assay. The linearity of the plots shows the 
equal amplification of the assay over a range of input DNA concentrations. The superimposition of the plots proved that each 
assay was equally efficient despite the relative difference in product size (84, 98 and 122 bp), and allowed a comparison 
between genes. The coefficient of correlation for GAPDH (triangles) was R = -0.997); for signal TREC (squares) was R= -0.980 
and for coding TREC (diamonds) was R= -0.995. B). GAPDH real-time readout is a reliable measure of the DNA con-
centration of a sample. Forty DNA samples were obtained independently from PBMCs, and their concentration was deter-
mined by measuring their OD at 260 nm (two readings were made for each sample at four different dilutions n = 8, reading at 
280 nm were taken and ratio of OD 260/OD 280 were all > 1,8). A SYBR-Green I real-time quantification of GAPDH was then 
performed, giving a second independent estimate of DNA concentration. We observed a significant correlation (R= -0.842, P < 
0.001) between the concentrations estimated by real-time Ct and by OD measurement in each sample.
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Together these results validate the use of GAPDH-Cts as an
internal measure of the amount of DNA in each sample,
reflecting the number of cells present in that sample.
Validation of the TRECs quantification assay
The original PCR conditions described in the reports by
Doueck and colleagues [14] were reproduced to clone two
PCR products (380 bp each) for both signal and coding
TRECs. Real-time PCR primers were designed flanking the
site of the recombination, to amplify PCR products of 99
and 122 bp, specific for signal and coding TRECs respec-
tively (see Figure 1). Optimisation and standardisation
were performed (see Figure 2 and 3). Two quantification
methods were used to compare a set of DNA samples
extracted from CD4+T-cells in ten healthy individuals.
The first method determined the number of TREC mole-
cules per µg of DNA, relying on DNA concentration
obtained by optical density readings. Our results were in
line with published values [14,15] for a similar age group
(Figure 4A). The second method estimated the number of
cells in the reaction by quantifying GAPDH copy number
as described above, giving the number of cells containing
a TREC as a percentage of total cells (Figure 4A). Results
obtained with these methods were comparable and could
be super-imposed. The second method has the advantage
of providing a more understandable scale. This method
was validated on a sorted cell population of less than fifty
cells (data not shown), demonstrating that it could be
adapted to samples with a very small yield of DNA [16].
The reproducibility of the PCR assay was determined by
including a standardisation sample in 17 consecutive PCR
plates, run by 2 independent manipulators (Figure 4C). In
this particular sample, the mean TREC content was 9.08
%, with a standard deviation of 0.611 %.
Validation for an assay detecting gene amplification
We next assessed the general applicability of our experi-
mental procedure to determine levels of relative gene
amplification. We used our assay to quantify GLI copy
number in genomic DNA extracted from cell lines known
to exhibit GLI gene amplification at various levels [17].
We proceeded through optimisation as in Figure 2. Anal-
ysis using our assay indicated slightly higher levels of
amplification (black bars) than previously reported (open
bars) [18] (Figure 5A). Similar results were observed when
multiplex-fluorescent PCR was used to analyse GLI copy
number in the DNA extracted from these cell lines (grey
bars). We also looked for evidence of MYC-C gene
amplification in two cell lines HT29 and colo320 [19] and
in normal PBMCs using our assay. After performing
optimisation, results (black bars) were similar to pub-
lished amplification levels (open bars) for both cell lines
but were normal in healthy PBMCs (Figure 5A).
We also applied the SYBR-Green I assay to tumour sam-
ples for the detection of the MYC-N gene amplification.
These samples had been tested previously by standard
procedures for the diagnosis of neuroblastoma using flu-
orescence in-situ hybridisation (FISH) [10]. Our results
(Figure 5B, black bars) compared well with the estab-
lished amplification factor recorded for these tumours
(open bars) and confirmed the presence of MYC-N ampli-
fication in 6 tumours. Using the ∆-∆Ct methods of calcu-
lation with one of the sample becoming the reference
(either sample 4777, 100 fold amplification or sample
4334, 50 fold amplification) does not change the results
significantly.
Validation for an assay detecting gene deletion in genomic 
DNA
Point mutations and small insertions or deletions in the
OPA1 gene have been shown to underlie more than half
of all cases of dominant optic atrophy. In addition two
larger deletions in OPA1 have been detected, each in a sin-
gle family. One of these deletes exon 20 and the surround-
ing intronic DNA [13], while the other deletes the entire
gene and over half a megabase of surrounding DNA [12].
Traditional PCR-based mutation detection methods such
as single strand contamination polymorphism (SSCP)
analysis would miss these mutations since only the nor-
mal allele would amplify. We therefore designed a SYBR-
Green I assay to quantify the number of copies of OPA1
exon 20 present in any given sample, which should there-
fore detect both of these deletions. We tested this on
genomic DNA from patients and healthy members of the
family (Figure 6A) with the deletion of the entire gene,
and were able to confirm a reduction in relative copy
number in these samples as compared to healthy mem-
bers of the family (figure 6B and 6C). In this particular
assay, exon 20 of the OPA1 gene is the target sequence. It
is 165 bp long and limited the design of exon specific
primers. The ratio of target gene to reference obtained in
normal PBMCs during optimisation was 0.96 (Figure 2C
and Table 1). However, the ∆Cts in affected individual
was on average more than 1 cycle compared to unaffected
individuals indicating a reduction of at least 50%. We also
applied this assay to the quantification of gene copy
number in a transgenic mouse model. The gene Hop was
5' FLAG-tagged. Endogenous Hop sequences were also
used as reference gene for the quantification. We
identified founders carrying either 1 or 2 copies of the
transgene (data not shown).
Discussion
There are major advantages of using real-time PCR com-
pared to conventional semi-quantitative PCR. Firstly, the
progression of the PCR reaction may be monitored after
each cycle rather than at the end, thereby providing a
much better quantification assay; secondly, very littlePage 7 of 13
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BMC Biotechnology 2003, 3 http://www.biomedcentral.com/1472-6750/3/18Absolute and relative quantifications of TREC determined using the SYBR-Green I assay are equivalentFigure 4
Absolute and relative quantifications of TREC determined using the SYBR-Green I assay are equivalent. We 
performed a quantification of TRECs by two methods. (A) Samples were quantified against a standard curve run in parallel 
with the samples, to obtain an absolute quantity of TRECs per µg of DNA. The results are described by the equation y = 
96911exp(-0.0562x) where x represents age (years) and y TRECs per µg of DNA (extracted from CD4+T-cells) using an 
exponential regression model (B) A GAPDH and a TREC assay were run in parallel to normalize the number of TRECs to the 
number of CD4+T-cells in the sample. Linearity is described by the equation y = 69.013exp(-0.0432x) where x represents age 
(years) and y the proportion of cells containing a TREC. Both methods produced equivalent results as shown by the similarity 
in their equation parameters. C. The reproducibility of the second assay was tested using one sample, analyzed 17 times on 
consecutive PCR plates. There was 4.1% variability between the 17 measurements.
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BMC Biotechnology 2003, 3 http://www.biomedcentral.com/1472-6750/3/18Quantification of gene amplification by a SYBR-Green I assayFigure 5
Quantification of gene amplification by a SYBR-Green I assay. A) Gene amplification detected in cell lines. Cell 
lines with known levels of gene amplification (open bars) were tested for GLI [17] or MYC-C [19] gene amplification using real-
time PCR and/or QM-Multiplex PCR. Results obtained using the SYBR-Green I real-time assay (black bars, triplicates) corre-
lated well with the levels of amplification for both genes described previously in these cell-lines. However, QM-Multiplex PCR 
gave lower levels of amplification in two out of five samples compared to reported results. B) Detection of gene amplifica-
tion in DNA extracted from neuroblastoma tumor samples. Tumor samples with known levels of MYC-N gene ampli-
fication, established using standard FISH techniques (open bars, estimated 1, 10, 50 or 100 amplification fold were tested for 
MYC-N gene amplification using our real-time PCR assay (black bars, triplicate). Results obtained correlated well with reported 
levels and confirmed either the presence of an MYC-N gene amplification in 6 out of 9 tumors or its absence in 3 tumors.
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Quantification of gene deletion by a SYBR-Green I assay. A. Pedigree of an ADOA family with a deletion of the 
entire OPA1 gene. Carriers of the deletion are indicated with filled symbols and normal individuals with open symbols [12]. 
B. Real-time plot obtained for the quantification of the OPA1 gene deletion. Genomic DNA from 2 individuals (a 
carrier and a normal) was assayed for copy number of the OPA1 gene using the SYBR-Green I real-time PCR assay. Real-time 
OPA1 amplification plots for carriers (right panel) are consistently at least one cycle behind the plots obtained with GAPDH, 
while plots for GAPDH and OPA1 in non-carriers are almost superimposed (left panel). C. Quantification of the OPA1 gene 
deletion in 13 members of the family. DNA was extracted from family members indicated by letters on A. The OPA1 ver-
sus GAPDH PCR assay was performed. Non-carriers showed a ratio close to 1 for the GAPDH versus OPA1 quantification. In 
contrast, all carriers of the deletion showed a clear reduction in this ratio.
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finally it can be performed in approximately two hours.
The advantages of using SYBR-Green I quantification over
a 5'-nuclease assay with TaqMan probes are the relative
simplicity and the reduced cost of SYBR-Green I compared
to TaqMan probes. The assay we have designed provides
an accurate relative quantification of gene rearrangement,
gene deletion and gene amplification. The principle used
in this assay can be adapted to a large number of biologi-
cal systems and could therefore have a significant impact
on patient care by providing accurate results in a shorter
time. Another major advantage of our assay is that it can
be carried out with only a few biopsy cells. Archived mate-
rial such as paraffin embedded tissue sections can be used.
DNA can be extracted from such material using the same
methodology (with no need for de-waxing) and used in a
SYBR-Green I real-time assay (data not shown). Therefore
our assay has significant advantages over other methods.
A real-time 5'-nuclease assay using TaqMan probes has
recently been described for the detection of TRECs [20].
However, this relies on an absolute quantification of
TRECs by normalisation to a standard curve using cloned
template. In our hands, a number of practical problems
were encountered with this approach. These included the
potential risk of cross-contamination of equipment with
the cloned template, the cost of repeating the standardisa-
tion but most importantly difficulties with quantification
of DNA in small samples. This latter problem is particu-
larly pertinent for following thymic function in biological
samples in which T-cells are depleted. Our strategy
allowed us to quantify TRECs in samples of less than one
hundred cells. The lowest number of cells from which we
were able to extract DNA and satisfactorily quantify TREC
was 70 cells (data not shown) [16]. TREC measurements
provide information about immune reconstitution in a
number of clinical situations, including anti-HIV-therapy,
chemotherapy and bone marrow or stem cell transplanta-
tion in cancer patients, and in autoimmune disease
patients [14,16,21,22]. Despite recent reports describing
the lack of a relationship between recent thymic activity
and TREC measurement in non-T-cell depleted host, with
controlled homeostasis [16,23], TREC are still the best
means of assessing thymic output in situation where there
are a limited number of T-cells to start with, such as fol-
lowing lymphodepletion achieved through therapeutical
means [chemotherapy, [24]] or caused by disease activity
(graft-versus-host disease [25] or viruses (HIV [20]).
Other gene rearrangements or translocations have been
studied using real-time PCR. For example, the major and
minor break-points of the chromosome 14 to 18 translo-
cation t(14:18)(q32;q21) have been analysed in non-
Hodgkins lymphomas using a 5'-nuclease assay with Taq-
Man probes [26] and results compared well with conven-
tional PCR (99 % concordance [27]). This TaqMan type of
assay could easily be replaced by a SYBR-Green I assay as
this simply reflects a change in the means of detection of
the PCR product.
Compared to Southern blotting or FISH when used for the
detection of gene amplification, our SYBR-Green I real-
time PCR assay provides a rapid and accurate alternative.
Furthermore, a FISH-based assay would require live mate-
rial, which may not be available or easy to obtain, whereas
the assay described here could be applied to tumour
derived DNA, which is much more readily available. The
use of the SYBR-Green I assay for the detection of gene
amplification could have an important impact for
patients as results are produced rapidly (in less than one
day) with a minimal amount of biopsy material. The diag-
nosis and treatment of a number of severe conditions
could benefit from the development of an assay based on
our findings. For example, the multi-drug resistance phe-
notype in tumours results from the amplification of the
MDR gene, which could be assayed quickly and cheaply as
described above [28]. Similarly, an assay could be devel-
oped to identify cyclin D1 and MDM2 gene amplification.
The former is a prognostic marker in breast carcinoma
[29] while the latter plays a role in the pathogenesis of a
variety of tumours [30].
Lastly we successfully detected the deletion of one allelic
copy of the OPA1 gene in an ADOA family. To date such
genetic abnormalities can only be detected unequivocally
by FISH. This requires live material and is therefore not
always possible. This assay could be applied to any gene
implicated in an autosomal dominant disease, in order to
determine whether whole or partial gene deletion is a sig-
nificant cause of disease. This SYBR green I assay could
also be applied to a number of conditions where a tumour
suppressor gene is involved in inherited susceptibility to
cancer (p53, Rb, WT1, APC, VHL or BRCA1). In these con-
ditions, one copy of the tumour suppressor gene is either
mutated or deleted in the germ line, while the second
copy is lost or mutated in the tumour itself. Genetic coun-
selling could therefore benefit from a quick and reliable
assay to determine carriers of such deletions.
Methods
Peripheral Blood Mononuclear cell (PBMC) recovery from 
blood samples and DNA extraction
PBMCs were recovered using a step gradient sucrose sepa-
ration procedure (Lymphoprep, Ficomed, Oslo, Norway)
from 5.0 ml of heparinized blood. DNA was extracted
using a standard proteinase K (Roche, Mannhein, Ger-
many) digestion (over night at 55°C) followed by phe-
nol/choloroform extraction (ready red, Appligen-Oncor,
Ilkirch France) and DNA precipitation using ethanol.
DNA was recovered by centrifugation, dissolved in TEPage 11 of 13
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For the TREC assay, a further CD4+ T-cell separation was
performed using magnetic depletion (CD4+ T-cell nega-
tive selection kit, Metachem, Meylan, France).
Real-time PCR
Real-time PCR was performed using an ABI 7700
Sequence Detection System (PE Applied-Biosystems) in
the presence of SYBR-green. The optimisation of the real-
time PCR reaction was performed according to the manu-
facturer's instructions (PE Applied-Biosystems, User Bul-
letin 2 applied to the SYBR-Green I core reagent protocol)
but scaled down to 25 µl per reaction. The PCR conditions
were standard (SYBR-Green I core reagent protocol) and
all reagents were provided in the SYBR-Green I core rea-
gent kit, including AmpliTaq-GOLD polymerase (PE
Applied-Biosystems). After optimisation (see Results sec-
tion), nucleotide primers were used at various concentra-
tions for the detection and quantification of GAPDH,
signal and coding TREC, GLI, MYC-C, MYC-N, OPA1,
FLAG and Hop.
Determination of the levels of gene amplification using 
QM-Multiplex PCR
Gene dosage of GLI was analysed by Fluorescent Differen-
tial PCR employing FAM labelled oligonucleotide primers
[18]. Two reference loci were also used: exon 19 of the
cystic fibrosis transmembrane conductance regulator
(CFTR) at 7q31 and ubiquitin-conjugating enzyme pseu-
dogene (UBE2L2) at 12q12. PCR amplification was car-
ried out in 30 µl 10 mM Tris-HCl buffer, pH 9.0,
containing 50 mM KCl, 0.1% (v/v) Triton X-100, 1.5 mM
MgCl2, 0.2 mM dNTPs, 5 µM of each primer for UBE2L2
and CFTR, 100 ng of genomic DNA, 7.5 µM of the GLI
primers and 2 units Taq DNA polymerase. PCR conditions
consisted of an initial denaturation step of 95°C for 5
minutes, followed by 24 cycles of 95°C for 1 minute,
58°C for 1 minute and 72°C for 1 minute, with a final
extension of 72°C for 10 minutes. A PCR using human
genomic DNA as a control was routinely run in parallel.
Moreover, experiments were performed in triplicate to
ensure reproducibility of the technique. The FAM labelled
products were separated through a denaturing polyacryla-
mide gel on an ABI 377 fragment analyser (PE Applied
Biosystems). Quantitative analysis of the PCR products
was performed using Genescan 672 software© (PE Applied
Biosystems). GLI gene dosage was calculated by compar-
ing the ratios of GLI to reference gene peak areas generated
by control DNA with those generated by the cell line
DNAs, as described [18]. Primer sequences were as fol-
lows: GLI-F-d TGA TGC AGT TCC TTT ATT ATC AGG; GLI-
R-(FAM)-d AGA GTA GGG AAT CTC ATC CAT CA, giving
a product of 200 bp. UB-F(FAM)-d CGA AGA GCA CAC
TTA AAG ATC TG; Ub-R-d GGT CAG CCT-GAA GTG GAT
GCT CA generating a 173 bp product. CFTR19-F-dCCT
ACC AAG TCA ACC AAA CC; CFTR19-R(FAM)-dACA TTG
CTT CAG GCT ACT GG; generating a product of 268 bp.
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